PPARA and metabolic dysfunction-associated steatohepatitis: In a mouse model of MASH, rifaximin was found to mitigate MASH by restoring gut, reversing intestinal barrier dysfunction, and modulating the expression of peroxisome proliferator-activated receptor (PPAR)α and PPARγ in the liver [97].